ArticleJournal of neuro-oncology2025
China National Glioma Registry (CNGR): protocol for a prospective observational registry study.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeGliomas present a significant public health challenge owing to their complex management and poor prognosis. Robust real-world datasets are essential for advancing glioma research and informing clinical practice. To address limitations of existing resources, we established the China National Glioma Registry (CNGR), a comprehensive, glioma-specific registry designed to systematically capture multidimensional data.
methodsThe CNGR is a prospective, longitudinal, observational registry initiated at Beijing Tiantan Hospital. Adult-type diffuse glioma patients are consecutively enrolled following informed consent. Clinical, pathological, imaging, functional, and long-term follow-up data are collected at predefined time points by trained specialists using standardized procedures and recorded in a secure electronic data capture system. All aspects of data acquisition and quality control are overseen by a dedicated multidisciplinary team to ensure accuracy, consistency, and integrity. The study protocol has been approved by the Ethics Committee of Beijing Tiantan Hospital and registered with the Chinese Clinical Trial Registry.
conclusionThe CNGR offers a structured framework for high-quality real-world data acquisition across the glioma disease trajectory. Although currently single-center, its nationwide recruitment ensures cohort diversity and broad applicability. The CNGR is intended to serve as a scalable model for future multi-center studies in neuro-oncology and as a robust research infrastructure to enhance diagnostic precision, inform therapeutic decision-making, and support prognostic evaluation. It is poised to become a valuable resource for translational research, evidence-based practice, and the development of personalized treatment strategies in glioma care.
trial registrationChinese Clinical Trial Registry (Clinical Trial Number: ChiCTR2400094600 , Date of Registration: 2024-12-25).
Indexed as
Identifiers
41247591What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.